Every 8-K that AMN Healthcare Services (AMN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMN filings page.
AMN Healthcare Services, Inc. posted second quarter 2026 revenue of $673 million, up 2% from a year earlier and down 51% sequentially following unusually large labor disruption events in the first quarter. Net income was $21 million, or $0.53 per diluted share, compared with a net loss of $116 million, or ($3.02) per share, in Q2 2025. Adjusted diluted EPS rose to $0.77 from $0.30, and adjusted EBITDA was $73 million, a 26% year-over-year increase with a 10.9% margin.
Nurse and Allied Solutions revenue was $422 million, up 11% year over year, helped by travel nurse and allied growth and $25 million of labor disruption revenue. Physician and Leadership Solutions revenue was $165 million, down 6% year over year, while Technology and Workforce Solutions revenue declined 15% to $87 million, with language services at $70 million and vendor management systems at $15 million.
Cash and cash equivalents totaled $362 million at June 30, 2026, against total debt of $750 million, resulting in a 1.5x leverage ratio under the company’s credit agreement. Operating cash flow was ($190 million) for the quarter and $373 million year to date, reflecting the return of client deposits from first-quarter labor disruption events. For the third quarter of 2026, management guides consolidated revenue to $640–$655 million and adjusted EBITDA margin to 6.5%–7.0%.
AMN Healthcare Services reported a very strong first quarter of 2026, with revenue of $1.378 billion, up 100% from a year earlier, and net income of $62 million or $1.59 per diluted share versus a prior-year loss. Adjusted diluted EPS rose to $2.10 from $0.45, while adjusted EBITDA reached $166.1 million, a 159% increase and a 12.1% margin. Nurse and Allied Solutions revenue grew to $1.127 billion, helped by $722 million from labor disruption events, and most staffing categories showed year-over-year growth, though Physician and Leadership Solutions and Technology and Workforce Solutions declined.
Cash flow from operations was $562 million, boosting cash to $561 million against $750 million of debt and a 1.6x leverage ratio. For second quarter 2026, AMN guided consolidated revenue to $620–$635 million with operating margin around breakeven and adjusted EBITDA margin of 6.7%–7.2%, signaling a step-down from the disruption-driven Q1 peak.
AMN Healthcare Services, Inc. reported the results of its Annual Meeting of Shareholders held on May 1, 2026. Shareholders approved Amendment No. 1 to the AMN Healthcare 2025 Equity Plan, which had previously been approved by the Board subject to shareholder approval.
All nine director nominees received strong support, with individual "for" votes generally around 27–29 million and broker non-votes of 4,410,527 for each nominee. In total, shareholders voted on five proposals, with detailed for, against, abstain, and broker non-vote tallies disclosed and further descriptions of each proposal referenced in the company’s Definitive Proxy Statement filed on March 18, 2026.
AMN Healthcare reported mixed fourth quarter and full-year 2025 results, with growth in some areas but sharply lower profitability. Q4 2025 revenue was $748 million, up 2% year over year and 18% sequentially, helped by $124 million of labor disruption revenue in Nurse and Allied Solutions. The quarter still produced a net loss of $7.7 million, or ($0.20) per share, while adjusted diluted EPS fell to $0.22, down 70% from the prior year period.
For full year 2025, revenue was $2.730 billion, down 8%, and AMN recorded a net loss of $95.7 million, or ($2.48) per share. Adjusted diluted EPS dropped to $1.36 from $3.31 in 2024, and adjusted EBITDA declined 31% to $234.5 million as gross margin compressed to 28.3%. Despite weaker earnings, cash flow from operations reached $269 million and total debt was reduced by $285 million to $775 million. For first quarter 2026, the company guides revenue to $1.225–$1.240 billion with an adjusted EBITDA margin of 9.7%–10.2%.
AMN Healthcare Services, Inc. announced that longtime director R. Jeffrey Harris plans to retire from its Board at the company’s 2026 annual meeting of shareholders and will not stand for re-election. The Board intends to nominate Eric Palmer, a veteran healthcare and insurance executive with more than 25 years of leadership experience, including senior roles at The Cigna Group and Evernorth Health Services, to stand for election at that meeting.
AMN Healthcare Services, Inc. will present at the J.P. Morgan Healthcare Conference on January 14, 2026. The company has prepared a slide presentation for this event, which is attached as Exhibit 99.1 and will also be available through the Investor Relations section of its website at https://ir.amnhealthcare.com/.
The information related to this conference appearance is being furnished under Item 7.01 and is not deemed filed under securities laws, meaning it will only be incorporated into other documents by specific reference. The report is signed on behalf of the company by Chief Executive Officer Cary Grace.
AMN Healthcare Services, Inc. reported that its Board of Directors approved amended and restated by-laws, effective immediately on December 11, 2025. The changes are designed to align its governance rules with current Delaware law and to tighten and clarify procedures around how stockholders call special meetings and bring business before meetings.
The updated by-laws refine the information and disclosure that stockholders must provide when nominating directors or submitting proposals, and they clarify the authority of the Board and the meeting chair to manage conduct at stockholder meetings. They also require director candidates to be available for interviews with Board members about their qualifications, while making additional ministerial and conforming updates.
AMN Healthcare Services, Inc. furnished an update on its business by reporting results for the fiscal quarter ended September 30, 2025. The company provided the details in a press release attached as Exhibit 99.1.
The information related to these quarterly results is furnished under Item 2.02 and, as stated, is not deemed “filed” under Section 18 of the Exchange Act. AMN’s common stock trades on the NYSE under the symbol AMN.
AMN Healthcare Services (AMN) completed a refinancing move as its subsidiary issued $400.0 million 6.500% Senior Notes due January 15, 2031, guaranteed on a senior unsecured basis by the parent and certain subsidiaries. Interest is payable semi-annually on January 15 and July 15, commencing July 15, 2026. The notes are callable at 103.250% in 2027, 101.625% in 2028, and 100% thereafter; before October 15, 2027, up to 40% may be redeemed with equity proceeds at 106.500%, or otherwise at par plus a make‑whole premium. A change of control triggers a 101% repurchase offer.
The company also amended its revolving credit facility to $450.0 million (from $750.0 million) and extended maturity to October 6, 2030, while updating leverage covenants (max 5.25x through March 31, 2027; 5.00x through June 30, 2028; 4.75x thereafter) and adding a pricing tier at Net Leverage ≥4.25x. AMN expects to draw about $100.0 million on the revolver and, together with note proceeds and cash, redeem all $500.0 million 2027 notes on October 22, 2025.
AMN Healthcare Services, Inc. reports that its subsidiary AMN Healthcare, Inc. plans an unregistered offering of $400 million aggregate principal amount of senior unsecured notes due 2031 and has announced the pricing of these 2031 Notes. The company also states that the issuer has delivered a Conditional Notice of Redemption for all $500 million aggregate principal amount of its outstanding senior unsecured notes due 2027, with redemption scheduled for October 22, 2025, subject to the successful completion of the 2031 Notes offering.
AMN Healthcare Services, Inc. plans a Fifth Amendment to its Credit Agreement that extends the maturity of its secured revolving credit facility to October 2030 from February 2028 while reducing the facility size from $750.0 million to $450.0 million. The amendment also removes the ten basis point credit spread adjustment tied to the Adjusted Term SOFR Adjustment.
The Consolidated Net Leverage Ratio covenant will be revised to be no greater than 5.25 to 1.00. A new pricing tier for a Net Leverage Ratio of at least 4.25x sets margins of 2.00% for SOFR loans, 1.00% for Base Rate Loans, 2.00% for the Letter of Credit Fee and 0.35% for the Unused Fee. The administrative agent has indicated sufficient lender consents, with final documentation expected in the fourth quarter of 2025.